Taiwan medical device company, Brain Navi, has today announced a new robot that will autonomously perform nasal swab tests. Driven by the current global pandemic, the robot prevents cross infections which will help to reduce the burden on medical systems and rebuild economies. The rapid spread of coronavirus resulted in lock-down policies around the world. Significant testing is now required as economies begin to reopen, but testing needs to be done safely and effectively to present further increases of spread.
The Brain Navi Nasal Swab Robot allows users to test safely at all times, so as to spare medical health care workers from the high-risk environment during sample collecting. With the unique robotic help, users can control the spread of the virus while waiting for a vaccine and prevent cross-infections.
In the middle of the COVID-19 world pandemic, the Bio Asia Taiwan 2020 exhibition still took place under high safety participation requirements. In this significant event, the Brain Navi Nasal Swab Robot was presented in public for the first time. It was a great honor to demonstrate the Robot’s functions to Taiwan’s President Tsai, Ing-wen, during the exhibition.
The newly developed Brain Navi “Nasal Swab Robot” helps to reduce staff-patient contact with highly infectious diseases at the point of testing by autonomously navigating and safely collecting patient samples. The Robot automatically recognizes the patient’s facial structure and the nostril’s location independently and gently takes the samples to avoid close contact with patients. The Brain Navi Nasal Swab Robot uses some fundamental functions of NaoTrac, the innovative “Neurosurgical navigation robot,” developed by Brain Navi, which successfully performed 15 Human trial cases at the Hualien Tzu-Chi Medical Center.
The Brain Navi Nasal Swab Robot’s application review of the Ministry of Health and Welfare’s clinical trial in Taiwan was approved. Brain Navi is in the process of approval in the US FDA for Emergency Use Authorization (EUA) and Taiwan TFDA.